litlas
Log inCreate account

Peter M. Ravdin

Active 1976–2021

57
Papers
26,762
Citations
52
h-index
57
i10-index

Citations

Citations per year for Peter M. Ravdin1977: 3 citations1978: 11 citations1979: 15 citations1980: 12 citations1981: 22 citations1982: 18 citations1983: 11 citations1984: 13 citations1985: 16 citations1986: 11 citations1987: 15 citations1988: 11 citations1989: 13 citations1990: 5 citations1991: 2 citations1992: 6 citations1993: 7 citations1994: 19 citations1995: 20 citations1996: 28 citations1997: 29 citations1998: 44 citations1999: 54 citations2000: 58 citations2001: 99 citations2002: 75 citations2003: 81 citations2004: 87 citations2005: 144 citations2006: 132 citations2007: 138 citations2008: 216 citations2009: 220 citations2010: 265 citations2011: 274 citations2012: 228 citations2013: 239 citations2014: 162 citations2015: 176 citations2016: 160 citations2017: 179 citations2018: 178 citations2019: 718 citations2020: 718 citations2021: 602 citations2022: 468 citations2023: 304 citations2024: 487 citations2025: 208 citations2026: 13 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,425 citing papers, 29.3% of this breakdownChina: 631 citing papers, 7.6% of this breakdownUnited Kingdom: 589 citing papers, 7.1% of this breakdownGermany: 402 citing papers, 4.9% of this breakdownItaly: 382 citing papers, 4.6% of this breakdownCanada: 359 citing papers, 4.3% of this breakdownNetherlands: 302 citing papers, 3.7% of this breakdownFrance: 301 citing papers, 3.6% of this breakdownAustralia: 196 citing papers, 2.4% of this breakdownSpain: 191 citing papers, 2.3% of this breakdownSwitzerland: 188 citing papers, 2.3% of this breakdownBelgium: 173 citing papers, 2.1% of this breakdown
0%29.3%Other 25.8%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology47.6%
  • Medicine39.9%
  • Computer Science4.2%
  • Health Professions1.4%
  • Neuroscience1.1%
  • Mathematics1%
  • Other4.8%

Topics

  • Breast Cancer Treatment Studies12.9%
  • HER2/EGFR in Cancer Research6%
  • Breast Lesions and Carcinomas4.1%
  • Cancer Genomics and Diagnostics3.2%
  • Estrogen and related hormone effects2.6%
  • Advanced Breast Cancer Therapies2.6%
  • Other68.6%

Coauthors

All papers

Open in search
  1. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Peter M. Ravdin, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, Jeffrey L. Berenberg, Jeffrey S. Abrams, George W. Sledge - New England Journal of Medicine 2018 cited by 2,369

  2. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

    Authors: Fátima Cardoso, Laura J. van’t Veer, Jan Bogaerts, Leen Slaets, Giuseppe Viale, Suzette Delaloge, Jean‐Yves Pierga, Étienne Brain, Sylvain Causeret, Mauro Delorenzi, Annuska M. Glas, Vassilis Golfinopoulos, Theodora Goulioti, Susan Knox, Erika Matos, Bart Meulemans, Peter A. Neijenhuis, Ulrike Nitz, Rodolfo Passalacqua, Peter M. Ravdin, Isabel T. Rubio, Mahasti Saghatchian, Tineke J. Smilde, Christos Sotiriou, Lisette Stork, Carolyn Straehle, Geraldine Thomas, Alastair M. Thompson, Jacobus M. van der Hoeven, Peter Vuylsteke, René Bernards, Konstantinos Tryfonidis, Emiel J. Rutgers, Martine Piccart - New England Journal of Medicine 2016 cited by 2,051

  3. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    Authors: Bernard Asselain, William E. Barlow, John M.S. Bartlett, Jonas Bergh, Elizabeth Bergsten-Nordström, Judith M. Bliss, Francesco Boccardo, Clare Boddington, Jan Bogaerts, Gianni Bonadonna, Rosie Bradley, Étienne Brain, Jeremy Braybrooke, Philippe Broët, John Bryant, Julie Ann Burrett, David Cameron, Mike Clarke, Alan S. Coates, Robert L. Coleman, Raoul Charles Coombes, Candace R. Correa, Joe Costantino, Jack Cuzick, David N. Danforth, Nancy E. Davidson, Christina Davies, Lucy Davies, Angelo Di Leo, David Dodwell, Mitch Dowsett, Frances Duane, Vaughan Evans, Marianne Ewertz, Bernard Fisher, John Forbes, Leslie G. Ford, J.-C. Gazet, Richard D. Gelber, Lucy Gettins, Luca Gianni, Michael Gnant, Jon Godwin, Aron Goldhirsch, Pamela J. Goodwin, Richard Gray, Daniel F. Hayes, Catherine Hill, James N. Ingle, Reshma Jagsi, R. Jakesz, Sam James, Wolfgang Janni, Hui Liu, Zulian Liu, Caroline Lohrisch, Sibylle Loibl, Liz MacKinnon, Andreas Makris, Eleftherios P. Mamounas, Gurdeep Mannu, Miguel Martín, S. Mathoulin, L. Mauriac, Paul McGale, Theresa McHugh, Philip Morris, Hirofumi Mukai, Larry Norton, Yasuo Ohashi, Ivo A. Olivotto, Soon Young Paik, Hongchao Pan, Richárd Pető, Martine Piccart, Lori J. Pierce, Philip Poortmans, Trevor J. Powles, K.I. Pritchard, Joseph Ragaz, Vinod Raina, Peter M. Ravdin, Simon Read, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Suzy Scholl, Dennis J. Slamon, Lidija Sölkner, Joseph A. Sparano, Seth M. Steinberg, Rosemary Sutcliffe, Sandra M. Swain, Carolyn Taylor, Andrew Tutt, Pinuccia Valagussa, Cornelis J.�H. van de Velde, Jos A. van der Hage, Giuseppe Viale, Gϋnter von Minckwitz and 10 more - The Lancet Oncology 2017 cited by 1,133

  4. Ki67 in breast cancer: prognostic and predictive potential

    Authors: Rinat Yerushalmi, Ryan Woods, Peter M. Ravdin, Malcolm Hayes, Karen A. Gelmon - The Lancet Oncology 2010 cited by 1,226

  5. Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Peter M. Ravdin, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Matthew P. Goetz, John A. Olson, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, Jeffrey L. Berenberg, Jeffrey S. Abrams, George W. Sledge - New England Journal of Medicine 2019 cited by 555

  6. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

    Authors: Joseph A. Sparano, Robert J. Gray, Della Makower, Kathleen I. Pritchard, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Edith A. Perez, John A. Olson, JoAnne Zujewski, Tracy Lively, Sunil Badve, Thomas J. Saphner, Lynne I. Wagner, Timothy J. Whelan, Matthew J. Ellis, Soonmyung Paik, William C. Wood, Peter M. Ravdin, Maccon Keane, Henry Gómez, Pavan S. Reddy, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia Kaklamani, James N. Atkins, Jeffrey L. Berenberg, George W. Sledge - New England Journal of Medicine 2015 cited by 1,439

  7. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

    Authors: Martine Piccart, Laura van ‘t Veer, Coralie Poncet, Josephine Lopes Cardozo, Suzette Delaloge, Jean‐Yves Pierga, Peter Vuylsteke, Étienne Brain, Suzan Vrijaldenhoven, Peter A. Neijenhuis, S. Causeret, Tineke J. Smilde, Giuseppe Viale, Annuska M. Glas, Mauro Delorenzi, Christos Sotiriou, Isabel T. Rubio, Sherko Kümmel, Gabriele Zoppoli, Alastair M. Thompson, Erika Matos, Khalil Zaman, Florentine Hilbers, Debora Fumagalli, Peter M. Ravdin, Susan Knox, Konstantinos Tryfonidis, Aleksandra Peric, Bart Meulemans, Jan Bogaerts, Fátima Cardoso, Emiel J. Rutgers - The Lancet Oncology 2021 cited by 358

  8. The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

    Authors: Jeffrey S. Ross, Elzbieta Slodkowska, W. Fraser Symmans, Lajos Pusztai, Peter M. Ravdin, Gabriel N. Hortobágyi - The Oncologist 2009 cited by 1,153

  9. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial

    Authors: Kathy S. Albain, William E. Barlow, Steven Shak, Gabriel N. Hortobágyi, Robert B. Livingston, I‐Tien Yeh, Peter M. Ravdin, Roberto Bugarini, Frederick L. Baehner, Nancy E. Davidson, George W. Sledge, Eric P. Winer, Clifford A. Hudis, James N. Ingle, Edith A. Perez, Kathleen I. Pritchard, Lois E. Shepherd, Julie R. Gralow, Carl Yoshizawa, D. Craig Allred, C. Kent Osborne, Daniel F. Hayes - The Lancet Oncology 2009 cited by 1,405

  10. American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer

    Authors: Lyndsay N. Harris, Herbert A. Fritsche, Robert Mennel, Larry Norton, Peter M. Ravdin, Sheila E. Taube, Mark R. Somerfield, Daniel F. Hayes, Robert C. Bast - Journal of Clinical Oncology 2007 cited by 2,216

  11. Estrogen Plus Progestin and Breast Cancer Incidence and Mortality in Postmenopausal Women

    Authors: Rowan T. Chlebowski, Garnet L. Anderson, Margery Gass, Dorothy S. Lane, Aaron K. Aragaki, Lewis H. Kuller, JoAnn E. Manson, Marcia L. Stefanick, Judith K. Ockene, Gloria E. Sarto, Karen Johnson, Jean Wactawski‐Wende, Peter M. Ravdin, Robert S. Schenken, Susan L. Hendrix, Aleksandar Rajkovic, Thomas E. Rohan, Shagufta Yasmeen, Ross L. Prentice, for the WHI Investigators - JAMA 2010 cited by 565

  12. High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

    Authors: Ana M. González-Angulo, Jennifer K. Litton, Kristine Broglio, Funda Meric‐Bernstam, Ronjay Rakkhit, Fátima Cardoso, Florentia Peintinger, Emer O. Hanrahan, Ayşegül A. Şahin, Merih Güray, Denis Larsimont, Francesco Feoli, Heidi Stranzl, Thomas A. Buchholz, Vicente Valero, Richard L. Theriault, Martine Piccart, Peter M. Ravdin, Donald A. Berry, Gabriel N. Hortobágyi - Journal of Clinical Oncology 2009 cited by 467

  13. The Decrease in Breast-Cancer Incidence in 2003 in the United States

    Authors: Peter M. Ravdin, Kathleen A. Cronin, Nadia Howlader, Christine D. Berg, Rowan T. Chlebowski, Eric J. Feuer, Brenda K. Edwards, Donald A. Berry - New England Journal of Medicine 2007 cited by 977

  14. Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer

    Authors: Stephen E. Jones, John K. Erban, Beth Overmoyer, G. T. Budd, Laura F. Hutchins, EE Lower, Leslie Rodgers Laufman, S. Sundaram, W J Urba, Kathleen I. Pritchard, Robert Mennel, Donald Richards, Steven R. Olsen, Marlene Meyers, Peter M. Ravdin - Journal of Clinical Oncology 2005 cited by 547

  15. Computer Program to Assist in Making Decisions About Adjuvant Therapy for Women With Early Breast Cancer

    Authors: Peter M. Ravdin, Laura A. Siminoff, Greg Davis, Mary Beth Mercer, Joan Hewlett, Nancy Gerson, Helen L. Parker - Journal of Clinical Oncology 2001 cited by 1,009

  16. Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers

    Authors: D. F. Hayes, Robert C. Bast, Christopher E. Desch, Herbert A. Fritsche, Nancy E. Kemeny, J. Milburn Jessup, Gershon Y. Locker, J. S. Macdonald, Robert Mennel, Larry Norton, Peter M. Ravdin, Sheila E. Taube, R Winn - JNCI Journal of the National Cancer Institute 1996 cited by 752

  17. NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry

    Authors: D. Craig Allred, Robert W. Carlson, Donald A. Berry, Harold J. Burstein, Stephen B. Edge, Lori J. Goldstein, Allen M. Gown, M. Elizabeth Hammond, J. Dirk Iglehart, Susan J. Moench, Lori J. Pierce, Peter M. Ravdin, Stuart J. Schnitt, Antonio C. Wolff - Journal of the National Comprehensive Cancer Network 2009 cited by 142

  18. Breast Cancer after Use of Estrogen plus Progestin in Postmenopausal Women

    Authors: Rowan T. Chlebowski, Lewis H. Kuller, Ross L. Prentice, Marcia L. Stefanick, JoAnn E. Manson, Margery Gass, Aaron K. Aragaki, Judith K. Ockene, Dorothy S. Lane, Gloria E. Sarto, Aleksandar Rajkovic, Robert S. Schenken, Susan L. Hendrix, Peter M. Ravdin, Thomas E. Rohan, Shagufta Yasmeen, Garnet L. Anderson - New England Journal of Medicine 2009 cited by 468

  19. Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer

    Authors: Wendy A. Woodward, William E. Barlow, Reshma Jagsi, Thomas A. Buchholz, Steven Shak, Frederick L. Baehner, Timothy J. Whelan, Nancy E. Davidson, James N. Ingle, Tari A. King, Peter M. Ravdin, C. Kent Osborne, Debasish Tripathy, Robert B. Livingston, Julie R. Gralow, Gabriel N. Hortobágyi, Daniel F. Hayes, Kathy S. Albain - JAMA Oncology 2020 cited by 77

  20. 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology*

    Authors: Robert C. Bast, Peter M. Ravdin, Daniel F. Hayes, Susan Bates, Herbert A. Fritsche, J. Milburn Jessup, Nancy E. Kemeny, Gershon Y. Locker, Robert Mennel, Mark R. Somerfield - Journal of Clinical Oncology 2001 cited by 886

  21. Population-Based Validation of the Prognostic Model ADJUVANT! for Early Breast Cancer

    Authors: Ivo A. Olivotto, Chris Bajdik, Peter M. Ravdin, Caroline Speers, Andrew J. Coldman, B. Norris, Greg Davis, Stephen Chia, Karen A. Gelmon - Journal of Clinical Oncology 2005 cited by 572

  22. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

    Authors: René Bruno, Darcy A. Hille, A. Riva, Nicole Vivier, W.W. ten Bokkel Huinnink, A.T. van Oosterom, S.B. Kaye, Jaap Verweij, Frank V. Fossella, Vicente Valero, James R. Rigas, Andrew D. Seidman, B Chevallier, P. Fumoleau, Howard A. Burris, Peter M. Ravdin, Lewis B. Sheiner - Journal of Clinical Oncology 1998 cited by 423

  23. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial

    Authors: Kathy S. Albain, William E. Barlow, Peter M. Ravdin, William B. Farrar, Gary V. Burton, Steven J. Ketchel, Charles D. Cobau, Ellis Levine, James N. Ingle, Kathleen I. Pritchard, Allen S. Lichter, Daniel J. Schneider, Martin D. Abeloff, I. Craig Henderson, Hyman B. Muss, Stephanie Green, Danika L. Lew, Robert B. Livingston, Silvana Martino, C. Kent Osborne - The Lancet 2009 cited by 259

  24. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study

    Authors: Stella Mook, Marjanka K. Schmidt, Emiel J. Rutgers, Anthonie O. van de Velde, Otto Visser, Sterre M Rutgers, Nicola J. Armstrong, Laura J. van’t Veer, Peter M. Ravdin - The Lancet Oncology 2009 cited by 177